|  |  |  |  |
| --- | --- | --- | --- |
| Date | 18/08/2025 | Deadline | 16/09/2025 |

|  |
| --- |
| CONTACT |

|  |  |  |  |
| --- | --- | --- | --- |
| **Organisation** | Metagenopolis-INRAE | **Department** | INRAE transfert |
| **Contact person** | Dina Chokr; Karine Valeille | **Email** | [Dina.chokr@inrae.fr](mailto:Dina.chokr@inrae.fr); [Karine.valeille@inrae.fr](mailto:Karine.valeille@inrae.fr) |
| **City** | Jouy-en-Josas | **Website** | <https://mgps.eu/> |
| **Country** | France |  |  |

|  |
| --- |
| **Organisation type** |

|  |  |  |  |
| --- | --- | --- | --- |
| **Research organisation type** | Research Organisation  University  Company  Other | **Is your company a Small and Medium Sized Enterprise (SME\*)?**  **Number of employees:**  **50** | YES  NO |

Your enterprise is an SME if:

- it is engaged in **economic activity**

- it has **less than 250 employees**

- it has either an **annual turnover not exceeding €50M**, **or an balance sheet total not exceeding €43M**

- it is **autonomous**

*For the definition of SMEs, look at:* [*http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition\_en*](http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)

|  |
| --- |
| **Short introduction of key areas of institute’s research:**  **Metagenopolis (MGP)** specializes in advanced microbiota research and technologies, empowering innovation in human and animal health and nutrition. From the discovery to the development of microbiota-based biotics, biomarkers and therapeutics, MGP provides comprehensive support using integrated metagenomics, preclinical models, mechanistic exploration and multi-omics approaches. |

|  |  |
| --- | --- |
| **Former participation in an FP European project?**  **Acronym/Project title:**  **Activities performed:** | YES  NO   * Evotar (2011-2015): Antibioresistance * IHMS (2011-2018) : Standards and methods * Metacardis (2012-2018) : Cardiometabolic diseases * GEMMA (2018-2024) : Autism and intestinal microbiota * ERC HomoSymbiosus (2018-2024) : Restoring the human-microbe symbiosis * MicrobPredict (2018-2025) : Cirrhosis and human intestinal microbiota * Human microbiome Action (2021-2024) : CSA project coordinated by INRAE, bringing together 16 European partners with the aim of establishing an international consensus on the state of knowledge and practice of microbiota science * Micro-AI-ome (2023-2028) : Cancer colorectal and AI * Provided scientific advice, project planning, and technical expertise, including NDA-compliant study design tailored to research questions * Prepared quotes and contracts on a full-cost basis * Delivered reports, result presentations, and scientific publications |

|  |
| --- |
| **Expertise / Commitment offered** |

|  |  |
| --- | --- |
| **Description of your expertise:** | * **Biobanking: up to 1,000,000 storage of fecal and microbial DNA samples, with automated tracking and secure backups** * **High-throughput quantitative metagenomics** (WGS): whole-genome shotgun sequencing) for deep microbial profiling at the strain level and with functional annotation, powered by our **expert biostatisticians and bioinformaticians.** * **Fermenter System**: a physiologically relevant ex vivo gut model using human or animal fecal samples to simulate microbiota environments and assess microbiota-drug-food interactions. * **Functional Screening assays for microbiota-host communication** (barrier function, inflammation, metabolism, oxidative stress...) * **The French Gut Database**: a large-scale cohort targeting 100,000 volunteers, with microbial DNA already sequenced from 30,000 stool samples, and correlated with rich nutritional and clinical metadata. Enables biomarker discovery, disease modeling, patient stratification, and collaborative ancillary studies |
|  | |  |
| **Keywords specifying your expertise:** | * **Microbiome Research** * **Biobanking** * **Whole-Genome Shotgun Metagenomic Sequencing** * **Bioinformatics & Biostatistics** * **Microbiota–Drug–Food Interactions** * **Ex Vivo Gut Microbiota Fermentation Models** * **Microbiota–Host Interactions** * **Functional Screening Assays** * **Microbiota Mapping and Functional Analysis** * **Microbial Biomarker Discovery** * **Disease Modeling & Patient Stratification** * **Clinical & Nutritional Metadata Integration** |
|  | |  |
| **Commitment offered:** | Research  Demonstration  Training  Technology  Dissemination  Other: |

|  |  |  |  |
| --- | --- | --- | --- |
| **Interested in participation in project types:** | Research & Innovation Action | Innovation Action | EIC Pathfinder |

|  |
| --- |
| Work Programme research areas: indicate your interest |

|  |
| --- |
| **Health** |

|  |
| --- |
| **Call topic(s):**  **HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections**  **HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health**  **HORIZON-MISS-2025-02-CANCER-05: Pragmatic clinical trials to enhance the quality of life of older cancer patients (65 years and older) through nutrition** |

|  |  |
| --- | --- |
| **Do you have other partners for this topic (which partners/country)?** | No |

|  |
| --- |
| Profile of partner sought |

|  |  |  |  |
| --- | --- | --- | --- |
| **Role** | technology development | research | training |
|  | dissemination | demonstration | other: New collaborations or joining consortia under development |
| **Country /region** | Any | | |
| **Expertise required** | * Clinical partners with access to patient cohorts * Data scientists/AI experts for predicting microbiome tools * Developers of microbiome-based therapeutics or diagnostics * Nutrition and food innovation experts * Regulatory and translational science partners | | |

**I agree with the publication of my contact data:**  YES  NO